《艾昆纬（IQVIA）：2025释放生物类似药潜力：骨质疏松症患者案例研究报告（英文版）（28页）.pdf》由会员分享，可在线阅读，更多相关《艾昆纬（IQVIA）：2025释放生物类似药潜力：骨质疏松症患者案例研究报告（英文版）（28页）.pdf（28页珍藏版）》请在三个皮匠报告上搜索。

1、MAY202 5Learnings from an Osteoporosis Case Study of Complex Patient PathwaysUnlocking Biosimilar PotentialBiosimilar use is growing globally,with more physicians becoming experienced and comfortable with their use.These biosimilars have also provided substantial savings for the overall healthcare s

2、ystem.In 2023,IQVIA Institute published a report highlighting the importance of physician perspectives on biosimilars for their optimal utilization.This viewpoint continues to remain relevant,particularly as biosimilars enter new disease areas,including ones that involve complex interactions with a

3、broad set of healthcare professionals.In such cases,different physician groups within a disease area may have varied experience with biosimilars.Ensuring that all groups are comfortable with and have knowledge about biosimilars is crucial to continue to gain the benefits from these biosimilars.This

4、report presents a case study of osteoporosis which expects to see the entry of biosimilars in 2025.Osteoporosis has a complex patient pathway,which involves several healthcare professionals and different stages.Additionally,the patient pathway and the specialists involved can vary substantially acro

5、ss countries and disease stages in Europe.The degree of familiarity and prior experience with biosimilars is likely to be highly variable across physician groups with some groups having never prescribed biosimilars.This report provides the results of a survey of several physicians that are involved

6、in the treatment and management of osteoporosis.The survey aims to understand the current state of knowledge about biosimilars across physician groups and potential barriers to optimal biosimilar use from a physician perspective.The report utilizes the survey findings to highlight some possible solu